ATE119393T1 - Verwendung eines opiatantagonisten zur herstellung eines transdermal zu verabreichenden arzneimittels sowie eine vorrichtung zur transdermalen verabreichung. - Google Patents

Verwendung eines opiatantagonisten zur herstellung eines transdermal zu verabreichenden arzneimittels sowie eine vorrichtung zur transdermalen verabreichung.

Info

Publication number
ATE119393T1
ATE119393T1 AT90122076T AT90122076T ATE119393T1 AT E119393 T1 ATE119393 T1 AT E119393T1 AT 90122076 T AT90122076 T AT 90122076T AT 90122076 T AT90122076 T AT 90122076T AT E119393 T1 ATE119393 T1 AT E119393T1
Authority
AT
Austria
Prior art keywords
transdermal administration
producing
opiate antagonist
medicinal product
antagonist
Prior art date
Application number
AT90122076T
Other languages
English (en)
Inventor
John David Sinclair
Original Assignee
Alko Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alko Ltd filed Critical Alko Ltd
Application granted granted Critical
Publication of ATE119393T1 publication Critical patent/ATE119393T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT90122076T 1989-11-20 1990-11-19 Verwendung eines opiatantagonisten zur herstellung eines transdermal zu verabreichenden arzneimittels sowie eine vorrichtung zur transdermalen verabreichung. ATE119393T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/439,050 US5096715A (en) 1989-11-20 1989-11-20 Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist

Publications (1)

Publication Number Publication Date
ATE119393T1 true ATE119393T1 (de) 1995-03-15

Family

ID=23743078

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90122076T ATE119393T1 (de) 1989-11-20 1990-11-19 Verwendung eines opiatantagonisten zur herstellung eines transdermal zu verabreichenden arzneimittels sowie eine vorrichtung zur transdermalen verabreichung.

Country Status (10)

Country Link
US (1) US5096715A (de)
EP (1) EP0429039B1 (de)
AT (1) ATE119393T1 (de)
AU (1) AU639042B2 (de)
CA (1) CA2030237C (de)
DE (1) DE69017596T2 (de)
DK (1) DK0429039T3 (de)
ES (1) ES2074513T3 (de)
FI (1) FI905718A7 (de)
NZ (2) NZ247173A (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
DE4223004A1 (de) * 1992-07-13 1994-01-20 Liedtke Pharmed Gmbh Einzeldosierte halbfeste topische Arzneiform zur Transdermaltherapie
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5580574A (en) * 1994-04-28 1996-12-03 Hoffmann-La Roche Inc. Pharmaceutical composition for transdermal delivery
US5552153A (en) * 1994-04-28 1996-09-03 Hoffman-La Roche Inc. Pharmaceutical composition for transdermal delivery
DE4423850A1 (de) * 1994-07-07 1996-01-11 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Naloxon
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
BR9813826A (pt) * 1997-12-22 2000-10-10 Euro Celtique Sa Potencial de uso abusivo de administração oral de opióide analgésico
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP2266564B1 (de) * 1997-12-22 2013-03-13 Euro-Celtique S.A. Peroral zu verabreichende Arzneiform enthaltend eine Kombination von einem opioid Agonisten und einem opioid Antagonisten
MXPA00012844A (es) 1998-07-07 2004-05-21 Transdermal Technologies Inc Composiciones para la liberacion transdermica rapida y sin irritacion de agentes farmaceuticamente activos y metodos para formular tales composiciones y liberar los mismos.
AU1807401A (en) * 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
EP2517710B1 (de) 2000-02-08 2015-03-25 Euro-Celtique S.A. Missbrauchssichere orale Opioidagonisten-Formulierungen
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US20060121103A1 (en) * 2000-05-11 2006-06-08 Kenneth Kirby Transdermal delivery system
US6569449B1 (en) 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
JP4522652B2 (ja) 2001-05-11 2010-08-11 エンドー ファーマシューティカルズ， インコーポレイティド 乱用防止制御放出オピオイド投薬形態
WO2003006980A1 (en) * 2001-07-13 2003-01-23 Arkray, Inc. Analyzing apparatus, piercing element integrally installed body for temperature measuring device with analyzing apparatus, and body fluid sampling apparatus
CA2454328C (en) * 2001-07-18 2008-03-18 Christopher D. Breder Pharmaceutical combinations of oxycodone and naloxone
MXPA04001210A (es) 2001-08-06 2004-07-08 Euro Celtique Sa Formulaciones de agonista opioide con antagonista liberable y aislado.
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
HUP0401022A3 (en) * 2001-08-14 2006-11-28 Biotie Therapies Corp Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
LT2425824T (lt) 2002-04-05 2017-07-25 Euro-Celtique S.A. Farmacinis preparatas, turintis oksikodono ir naloksono
SI1551372T1 (en) * 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
EP1613324A2 (de) * 2003-04-14 2006-01-11 Pain Therapeutics, Inc. Verfahren zur behandlung von schmerzen mit opioid-antagonisten
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP1604666A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US7910599B2 (en) 2005-01-10 2011-03-22 John David Sinclair Method for treating eating disorders by selective extinction with transdermal naloxone
EP1702558A1 (de) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2719378B1 (de) * 2006-06-19 2016-08-31 Alpharma Pharmaceuticals LLC Pharmazeutische Zusammensetzungen
JP2010531807A (ja) 2007-05-25 2010-09-30 トルマー セラピューティクス， インコーポレイテッド リスペリドン化合物の徐放送達製剤
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
EP2224808A4 (de) * 2007-12-17 2013-11-27 Alpharma Pharmaceuticals Llc Pharmazeutische zusammensetzung
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
WO2009106831A2 (en) 2008-02-28 2009-09-03 Syntropharma Limited Pharmaceutical composition
AU2009268011B2 (en) * 2008-07-07 2013-02-28 Mundipharma Pty Limited Use of opioid antagonists for treating urinary retention
HUE042105T2 (hu) 2009-03-10 2019-06-28 Euro Celtique Sa Oxikodont és naloxont tartalmazó azonnali hatóanyagleadású orális gyógyászati készítmények
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
EP3024461B1 (de) 2013-07-23 2020-05-13 Euro-Celtique S.A. Kombination aus oxycodon und naloxon für die verwendung bei der behandlung von schmerzen bei patienten mit schmerzen und einer krankheit, die zur intestinaldysbiose und/oder erhöhung der gefahr bakterieller translokation führt
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US11607026B2 (en) * 2014-05-30 2023-03-21 Johnson & Johnson Consumer Inc. Device for delivery of skin care composition
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
WO2019113470A1 (en) * 2017-12-08 2019-06-13 Teikoku Pharma Usa, Inc. Naloxone transdermal delivery devices and methods for using the same
EP4103181A4 (de) * 2020-02-14 2024-03-06 Teikoku Pharma USA, Inc. Topische naloxonzusammensetzung und verfahren zu deren verwendung

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2837881A (en) * 1952-12-13 1958-06-10 Lawrence A Schneider Encapsulated product and method and apparatus for making same
US3249109A (en) * 1963-11-01 1966-05-03 Maeth Harry Topical dressing
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
IE49783B1 (en) * 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
US4629539A (en) * 1982-07-08 1986-12-16 Tdk Corporation Metal layer patterning method
EP0116538A4 (de) * 1982-08-25 1985-04-25 Joel E Bernstein Verfahren zur behandlung von pruritis und zusammensetzung dazu.
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4818540A (en) * 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
DE3545926A1 (de) * 1985-12-23 1987-07-02 Allan Gerhard Fruehauf Tuch oder dgl. mit darin integrierten, einen wirkstoff enthaltenden kapseln
ATE77559T1 (de) * 1986-11-14 1992-07-15 Theratech Inc Erhoehung des penetrationsvermoegens mittels eines aus die zellhuelle veraendernden substanzen und kurzkettigen alkoholen bestehenden binaeren systems.
DE3862405D1 (de) * 1987-03-09 1991-05-23 Alza Corp Zusammensetzung zur vorbeugung einer kontaktallergie durch gleichzeitiges verabreichen eines kortikosteroids mit einem sensiblisierenden arzneistoff.
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response

Also Published As

Publication number Publication date
CA2030237A1 (en) 1991-05-21
CA2030237C (en) 1997-12-30
DK0429039T3 (da) 1995-03-27
US5096715A (en) 1992-03-17
AU6665090A (en) 1991-05-23
NZ236104A (en) 1993-04-28
ES2074513T3 (es) 1995-09-16
DE69017596T2 (de) 1995-07-06
FI905718L (fi) 1991-05-21
FI905718A7 (fi) 1991-05-21
DE69017596D1 (de) 1995-04-13
EP0429039A3 (en) 1991-10-16
FI905718A0 (fi) 1990-11-20
NZ247173A (en) 1997-07-27
EP0429039A2 (de) 1991-05-29
EP0429039B1 (de) 1995-03-08
AU639042B2 (en) 1993-07-15

Similar Documents

Publication Publication Date Title
ATE119393T1 (de) Verwendung eines opiatantagonisten zur herstellung eines transdermal zu verabreichenden arzneimittels sowie eine vorrichtung zur transdermalen verabreichung.
UA41502C2 (uk) Стабілізований фармацевтичний препарат, який містить гормон росту і гістидин, кристали гормону росту, що містять гістидин, та спосіб їх одержання
ATA164884A (de) Verfahren zur herstellung von festen, zweiphasigen nifedipinhaltigen arzneimittelzubereitungen
DE58906926D1 (de) Neue Arzneimittelformulierung sowie Verfahren zu deren Herstellung.
IL99699A0 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
MY107088A (en) Plaster used as therapeutic system for the administration of active substances to the skin, which exhibits a graduated active substance release,process for the production of the plaster and use thereof
IL87160A0 (en) Process for producing medicinal active substances by means of a printing process
DE58903856D1 (de) Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung.
DE58901002D1 (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken.
ATE99172T1 (de) Verwendung von acetyl-l-carnitin zur behandlung von katarakt, sowie pharmazeutische zusammensetzungen fuer eine derartige behandlung.
ATE206914T1 (de) Verwendung von ursolsäure zur herstellung eines arzneimittels zur unterdrückung von metastasen
ATE69724T1 (de) Selbstklebende vorrichtung zur transdermalen verabreichung eines wirkstoffs.
ATE27155T1 (de) Hexahydronaphth(1,2-b)-1,4-oxazine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
AU625402B2 (en) Transdermal system exhibiting graduated drug release and its use for the local or systemic administration of active substances
KR890006227A (ko) 페놀-함유 진해성 액체 조성물
DE3787477D1 (de) Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung.
DE69103624D1 (de) Ipriflavone enthaltende pharmazeutische zubereitungen, verfahren zur herstellung und therapeutische verwendung.
DE10004790A1 (de) Transdermales therapeutisches System zur Verabreichung von Zaleplon
Thomas et al. Cardiac arrhythmia during outpatient dental anaesthesia: the advantages of a controlled ventilation technique
DE345883T1 (de) Verwendung von dapiprazol zur herstellung eines arzneimittels zur verhinderung des toleranzentwicklung bei der analgetischen behandlung mit morphin.
ATE25090T1 (de) Pharmazeutische verbindungen, deren herstellung, anwendung, deren zwischenverbindungen und herstellung.
DE3786168D1 (de) Verwendung von para-aminobenzoesaeure zur herstellung eines arzneimittels zur bekaempfung von photoallergien.
ATE60333T1 (de) D-nor-7-ergolinderivate, verfahren zu ihrer herstellung, pharmazeutische zubereitung und verwendung.
Barzaghi et al. Pharmacokinetics of dextromoramide in surgical patients

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time